Disease control · bullous pemphigoid
It is very uncertain whether prednisone plus azathioprine changes disease control (at 6 months) compared with prednisone (very low certainty).
1 finding from 1 review
Mortality (at 6 months) · bullous pemphigoid
It is very uncertain whether prednisone plus azathioprine changes mortality (at 6 months) compared with prednisone (very low certainty).
1 finding from 1 review
Quality of life ‐ not measured · bullous pemphigoid
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events · bullous pemphigoid
1 finding from 1 review
Disease control (time when steroid could be discontinued) · bullous pemphigoid
1 finding from 1 review
Mortality at 1 year · bullous pemphigoid
It is very uncertain whether methylprednisolone plus azathioprine changes mortality at 1 year compared with methylprednisolone plus dapsone (very low certainty).
1 finding from 1 review
Quality of life ‐ not measured · bullous pemphigoid
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events at 1 year · bullous pemphigoid
1 finding from 1 review
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
Summary of findings table ‐ Oral classical immunosuppressants… showed no clear difference in short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with oral classical immunosuppressants (azathioprine, methotrexate,… (low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Health‐related quality of life ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete response · patients with cutaneous disease in systemic lupus erythematosus
Oral ciclosporin showed no clear difference in primary outcome: complete clinical response compared with oral azathioprine (low certainty).
1 finding from 1 review
Primary outcome: partial clinical response · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: clinical flare · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: CLASI · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral ciclosporin showed no clear difference in adverse events: severe compared with oral azathioprine (low certainty).
1 finding from 1 review
Adverse events: minor (hirsutism) · patients with cutaneous disease in systemic lupus erythematosus
Oral ciclosporin may leads to higher adverse events: minor (hirsutism) compared with oral azathioprine (low certainty).
1 finding from 1 review